Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming ‘vaccine resistant malaria’
暂无分享,去创建一个
[1] A. Dicko,et al. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. , 2009, Vaccine.
[2] V. A. Stewart,et al. Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in Western Kenya , 2009, PloS one.
[3] C. Withers-Martinez,et al. An Inhibitory Antibody Blocks Interactions between Components of the Malarial Invasion Machinery , 2009, PLoS pathogens.
[4] Victoria C. Barclay,et al. Mixed allele malaria vaccines: Host protection and within-host selection , 2008, Vaccine.
[5] Arlo Z. Randall,et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays , 2008, Proteomics.
[6] Srinivasan Ramachandran,et al. MalVac: Database of malarial vaccine candidates , 2008, Malaria Journal.
[7] Sergei L. Kosakovsky Pond,et al. Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: Implications for vaccine design , 2008, Proceedings of the National Academy of Sciences.
[8] A. Thomas,et al. A Diversity-Covering Approach to Immunization with Plasmodium falciparum Apical Membrane Antigen 1 Induces Broader Allelic Recognition and Growth Inhibition Responses in Rabbits , 2008, Infection and Immunity.
[9] A. Thomas,et al. Apical membrane antigen 1: a malaria vaccine candidate in review. , 2008, Trends in parasitology.
[10] Marcel Tanner,et al. Malaria eradication back on the table. , 2008, Bulletin of the World Health Organization.
[11] O. Branch,et al. Genetic diversity of vaccine candidate antigens in Plasmodium falciparum isolates from the Amazon basin of Peru , 2008, Malaria Journal.
[12] M. Enserink,et al. Did They Really Say ... Eradication? , 2007, Science.
[13] C. Drakeley,et al. How is childhood development of immunity to Plasmodium falciparum enhanced by certain antimalarial interventions? , 2007, Malaria Journal.
[14] Y. D. Sharma,et al. Sequence diversity and natural selection at domain I of the apical membrane antigen 1 among Indian Plasmodium falciparum populations , 2007, Malaria Journal.
[15] D. Crook,et al. Vaccine Escape Recombinants Emerge after Pneumococcal Vaccination in the United States , 2007, PLoS pathogens.
[16] A. Benito,et al. Liver stage antigen 3 isolated from a cDNA library of Plasmodium falciparum erythrocytic stages , 2007, Parasitology Research.
[17] J. Vulule,et al. A polymerase chain reaction/ligase detection reaction fluorescent microsphere assay to determine Plasmodium falciparum MSP-119 haplotypes. , 2007, The American journal of tropical medicine and hygiene.
[18] A. Batchelor,et al. Structural basis of antigenic escape of a malaria vaccine candidate , 2007, Proceedings of the National Academy of Sciences.
[19] B. Kanoi,et al. New concepts in vaccine development in malaria , 2007, Current opinion in infectious diseases.
[20] M. Good,et al. A case for whole-parasite malaria vaccines. , 2007, International journal for parasitology.
[21] A. Thomas,et al. Fine Mapping of an Epitope Recognized by an Invasion-inhibitory Monoclonal Antibody on the Malaria Vaccine Candidate Apical Membrane Antigen 1* , 2007, Journal of Biological Chemistry.
[22] S. Kariuki,et al. A comparative study of the genetic diversity of the 42kDa fragment of the merozoite surface protein 1 in Plasmodium falciparum and P. vivax. , 2007, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[23] David L. Smith,et al. World Health Organization , 2016, International Encyclopedia of Public Health.
[24] D. Conway,et al. Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. , 2007, The Journal of infectious diseases.
[25] D. Conway,et al. Differential evidence of natural selection on two leading sporozoite stage malaria vaccine candidate antigens. , 2007, International journal for parasitology.
[26] M. Enserink,et al. Malaria. Did they really say ... eradication? , 2007, Science.
[27] D. Conway,et al. RTS,S/AS02A Malaria Vaccine Does Not Induce Parasite CSP T Cell Epitope Selection and Reduces Multiplicity of Infection , 2006, PLoS clinical trials.
[28] S. Kaplan,et al. Streptococcus pneumoniae Serogroups 15 and 33: An Increasing Cause of Pneumococcal Infections in Children in the United States After the Introduction of the Pneumococcal 7-Valent Conjugate Vaccine , 2006, The Pediatric infectious disease journal.
[29] J. Ohashi,et al. Sequence Variation in the T-Cell Epitopes of the Plasmodium falciparum Circumsporozoite Protein among Field Isolates Is Temporally Stable: a 5-Year Longitudinal Study in Southern Vietnam , 2006, Journal of Clinical Microbiology.
[30] C. Whitney,et al. Pre- and Postvaccination Clonal Compositions of Invasive Pneumococcal Serotypes for Isolates Collected in the United States in 1999, 2001, and 2002 , 2006, Journal of Clinical Microbiology.
[31] Patricia De la Vega,et al. Development, Characterization and Immunogenicity of a Multi-Stage, Multivalent Plasmodium falciparum Vaccine Antigen (FALVAC-1A) Expressed in Escherichia coli , 2006, Human vaccines.
[32] L. Rénia,et al. Are Extensive T Cell Epitope Polymorphisms in the Plasmodium falciparum Circumsporozoite Antigen, a Leading Sporozoite Vaccine Candidate, Selected by Immune Pressure?1 , 2005, The Journal of Immunology.
[33] Aditi Gupta,et al. Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[34] R. Rappuoli,et al. The impact of genomics on vaccine design. , 2005, Trends in biotechnology.
[35] V. Murphy,et al. Allele Specificity of Naturally Acquired Antibody Responses against Plasmodium falciparum Apical Membrane Antigen 1 , 2005, Infection and Immunity.
[36] D. Conway,et al. Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. , 2004, Vaccine.
[37] Inacio Mandomando,et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial , 2004, The Lancet.
[38] C. John,et al. Evidence That Invasion-Inhibitory Antibodies Specific for the 19-kDa Fragment of Merozoite Surface Protein-1 (MSP-119) Can Play a Protective Role against Blood-Stage Plasmodium falciparum Infection in Individuals in a Malaria Endemic Area of Africa1 , 2004, The Journal of Immunology.
[39] M. Molyneux,et al. Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection , 2004, The Lancet.
[40] A. Cowman,et al. Allelic polymorphisms in apical membrane antigen‐1 are responsible for evasion of antibody‐mediated inhibition in Plasmodium falciparum , 2004, Molecular microbiology.
[41] Markus S. Mueller,et al. A Role for Apical Membrane Antigen 1 during Invasion of Hepatocytes by Plasmodium falciparum Sporozoites* , 2004, Journal of Biological Chemistry.
[42] A. Holder,et al. Fine Specificity of Serum Antibodies to Plasmodium falciparum Merozoite Surface Protein, PfMSP-119, Predicts Protection from Malaria Infection and High-Density Parasitemia , 2004, Infection and Immunity.
[43] A. Thomas,et al. Apical Membrane Antigen 1, a Major Malaria Vaccine Candidate, Mediates the Close Attachment of Invasive Merozoites to Host Red Blood Cells , 2004, Infection and Immunity.
[44] S. Hoffman,et al. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine , 2003, Journal of Experimental Biology.
[45] D. Conway,et al. Allele frequency-based analyses robustly map sequence sites under balancing selection in a malaria vaccine candidate antigen. , 2003, Genetics.
[46] T. Horii,et al. Sequence diversity in the amino-terminal region of the malaria-vaccine candidate serine repeat antigen in natural Plasmodium falciparum populations. , 2003, Parasitology international.
[47] J. Haynes,et al. Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine. , 2003, Molecular and biochemical parasitology.
[48] R. Anders,et al. Geographical Structure of Diversity and Differences between Symptomatic and Asymptomatic Infections for Plasmodium falciparum Vaccine Candidate AMA1 , 2003, Infection and Immunity.
[49] A. P. Tonon,et al. Sequence diversity and evolution of the malaria vaccine candidate merozoite surface protein-1 (MSP-1) of Plasmodium falciparum. , 2003, Gene.
[50] A. Dicko,et al. Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. , 2002, The American journal of tropical medicine and hygiene.
[51] A. Saul,et al. In Vitro Studies with Recombinant Plasmodium falciparum Apical Membrane Antigen 1 (AMA1): Production and Activity of an AMA1 Vaccine and Generation of a Multiallelic Response , 2002, Infection and Immunity.
[52] J. Wootton,et al. Evidence for intragenic recombination in Plasmodium falciparum: identification of a novel allele family in block 2 of merozoite surface protein-1: Asembo Bay Area Cohort Project XIV. , 2002, Molecular and biochemical parasitology.
[53] S. Kariuki,et al. A study of genetic diversity in the gene encoding the circumsporozoite protein (CSP) of Plasmodium falciparum from different transmission areas--XVI. Asembo Bay Cohort Project. , 2002, Molecular and biochemical parasitology.
[54] David L. Tabb,et al. A proteomic view of the Plasmodium falciparum life cycle , 2002, Nature.
[55] A. Holder,et al. The Human Immune Response to Plasmodium falciparum Includes Both Antibodies That Inhibit Merozoite Surface Protein 1 Secondary Processing and Blocking Antibodies , 2002, Infection and Immunity.
[56] Danny W. Wilson,et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum , 2002, The Lancet.
[57] A. Thomas,et al. High-Level Expression of the Malaria Blood-Stage Vaccine Candidate Plasmodium falciparum Apical Membrane Antigen 1 and Induction of Antibodies That Inhibit Erythrocyte Invasion , 2002, Infection and Immunity.
[58] Thomas A. Smith,et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. , 2002, The Journal of infectious diseases.
[59] O. Branch,et al. Antibody responses to repetitive epitopes of the circumsporozoite protein, liver stage antigen-1, and merozoite surface protein-2 in infants residing in a Plasmodium falciparum-hyperendemic area of western Kenya. XIII. Asembo Bay Cohort Project. , 2002, The American journal of tropical medicine and hygiene.
[60] B. Nahlen,et al. Polymorphism in the gene encoding the Pfs48/45 antigen of Plasmodium falciparum. XI. Asembo Bay Cohort Project. , 2002, Molecular and biochemical parasitology.
[61] B. Nahlen,et al. Longitudinal study of natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in a holoendemic region of malaria in western Kenya: Asembo Bay Cohort Project VIII. , 2001, The American journal of tropical medicine and hygiene.
[62] D. Conway,et al. Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene. , 2001, Genetics.
[63] S. Hoffman,et al. DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation. , 2001, International journal for parasitology.
[64] R. Anders,et al. Specificity of the Protective Antibody Response to Apical Membrane Antigen 1 , 2001, Infection and Immunity.
[65] B. Nahlen,et al. Polymorphism in the gene encoding the apical membrane antigen-1 (AMA-1) of Plasmodium falciparum. X. Asembo Bay Cohort Project. , 2001, Molecular and biochemical parasitology.
[66] D. Kaslow,et al. Short report: IgG1/IgG3 antibody responses to various analogs of recombinant ypfmsp119--a study in immune adults living in areas of Plasmodium falciparum transmission. , 2001, The American journal of tropical medicine and hygiene.
[67] Interpretability and robustness of sieve analysis models for assessing HIV strain variations in vaccine efficacy. , 2001, Statistics in medicine.
[68] L. BenMohamed,et al. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3 , 2000, Nature Medicine.
[69] S. Hoffman,et al. HLA degenerate T‐cell epitopes from Plasmodium falciparum liver stage‐specific antigen 1 (LSA‐1) are highly conserved in isolates from geographically distinct areas , 2000, Parasite immunology.
[70] D. Conway,et al. Allelic lineages of the merozoite surface protein 3 gene in Plasmodium reichenowi and Plasmodium falciparum. , 2000, Molecular and biochemical parasitology.
[71] D. Conway,et al. Molecular characterisation of Plasmodium reichenowi apical membrane antigen-1 (AMA-1), comparison with P. falciparum AMA-1, and antibody-mediated inhibition of red cell invasion. , 2000, Molecular and biochemical parasitology.
[72] D. Conway,et al. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses , 2000, Nature Medicine.
[73] O. Branch,et al. Anti-merozoite surface protein-1 19-kDa IgG in mother-infant pairs naturally exposed to Plasmodium falciparum: subclass analysis with age, exposure to asexual parasitemia, and protection against malaria. V. The Asembo Bay Cohort Project. , 2000, The Journal of infectious diseases.
[74] D. Conway,et al. High-throughput sequence typing of T-cell epitope polymorphisms in Plasmodium falciparum circumsporozoite protein. , 2000, Molecular and biochemical parasitology.
[75] M. Aidoo,et al. Field studies of cytotoxic T lymphocytes in malaria infections: implications for malaria vaccine development. , 2000, Parasitology today.
[76] O. Kaneko,et al. Selection and genetic drift of polymorphisms within the merozoite surface protein-1 gene of Plasmodium falciparum. , 2000, Gene.
[77] M. Aidoo,et al. Cytotoxic T-Lymphocyte Epitopes for HLA-B53 and Other HLA Types in the Malaria Vaccine Candidate Liver-Stage Antigen 3 , 2000, Infection and Immunity.
[78] R. Coppel,et al. A Plasmodium falciparum apical membrane antigen-1 (AMA-1) gene apparently generated by intragenic recombination. , 1999, Molecular and biochemical parasitology.
[79] D. Conway,et al. Allelic recombination and linkage disequilibrium within Msp-1 of Plasmodium falciparum, the malignant human malaria parasite. , 1999, Gene.
[80] B. Nahlen,et al. Predicted and observed alleles of Plasmodium falciparum merozoite surface protein-1 (MSP-1), a potential malaria vaccine antigen. , 1998, Molecular and biochemical parasitology.
[81] F. Ayala,et al. Genetic polymorphism and natural selection in the malaria parasite Plasmodium falciparum. , 1998, Genetics.
[82] O. Branch,et al. A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. , 1998, The American journal of tropical medicine and hygiene.
[83] F. Ayala,et al. Escalante AA, Lal AA, Ayala FJ. Genetic polymorphism and natural selection in the malaria parasite Plasmodium falciparum. Genetics 149: 189-202 , 1998 .
[84] Irwin W. Sherman,et al. Malaria : parasite biology, pathogenesis, and protection , 1998 .
[85] F. Ayala,et al. Plasmodium falciparum antigenic diversity: evidence of clonal population structure. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[86] A. Holder,et al. Antibodies that Inhibit Malaria Merozoite Surface Protein–1 Processing and Erythrocyte Invasion Are Blocked by Naturally Acquired Human Antibodies , 1997, The Journal of experimental medicine.
[87] M. Aidoo,et al. Cytotoxic T cell reactivity and HLA‐B35 binding of the variant Plasmodium falciparum circumsporozoite protein CD8+ CTL epitope in naturally exposed Kenyan adults , 1997, European journal of immunology.
[88] H. Lipps,et al. Limited sequence polymorphism in the Plasmodium falciparum merozoite surface protein 3. , 1997, Molecular and biochemical parasitology.
[89] T. Horii,et al. Sequence diversity in the amino-terminal 47 kDa fragment of the Plasmodium falciparum serine repeat antigen. , 1997, Molecular and biochemical parasitology.
[90] R. Moritz,et al. The Disulfide Bond Structure of Plasmodium Apical Membrane Antigen-1* , 1996, The Journal of Biological Chemistry.
[91] E. Paoletti,et al. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria , 1996, Infection and immunity.
[92] W. Hawley,et al. Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1 , 1996, Infection and immunity.
[93] R. Coppel,et al. Diversity of the vaccine candidate AMA-1 of Plasmodium falciparum. , 1996, Molecular and biochemical parasitology.
[94] A. Holder,et al. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. , 1996, The Journal of infectious diseases.
[95] S. Hoffman,et al. Preventing sporozoite invasion of hepatocytes. , 1996 .
[96] S. Hoffman,et al. Perspectives on malaria vaccine development. , 1996 .
[97] S. Hoffman. Malaria vaccine development: a multi-immune response approach , 1996 .
[98] O. Branch,et al. Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. , 1995, Journal of immunology.
[99] A. Holder,et al. Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum , 1995, Infection and immunity.
[100] R. Konings,et al. Minimal variation in the transmission-blocking vaccine candidate Pfs48/45 of the human malaria parasite Plasmodium falciparum. , 1995, Molecular and biochemical parasitology.
[101] C. Rogier,et al. High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1. , 1994, The American journal of tropical medicine and hygiene.
[102] A. Hughes,et al. Allelic variation in the circumsporozoite protein of Plasmodium falciparum from Thai field isolates. , 1994, The American journal of tropical medicine and hygiene.
[103] A. Thomas,et al. Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. , 1994, Molecular and biochemical parasitology.
[104] B. Chait,et al. Structural and functional properties of region II-plus of the malaria circumsporozoite protein , 1994, The Journal of experimental medicine.
[105] C. Khamboonruang,et al. Natural amino acid polymorphisms of the circumsporozoite protein of Plasmodium falciparum abrogate specific human CD4+ T cell responsiveness , 1994, European journal of immunology.
[106] T. McCutchan,et al. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). , 1993, Molecular and biochemical parasitology.
[107] M. Alpers,et al. Diversity in the immunodominant determinants of the circumsporozoite protein of Plasmodium falciparum parasites from malaria-endemic regions of Papua New Guinea and Brazil. , 1992, The American journal of tropical medicine and hygiene.
[108] A. Holder,et al. Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (Pf MSP1) of Plasmodium falciparum are associated with reduced malaria morbidity , 1992, Parasite immunology.
[109] D. Doolan,et al. Geographically restricted heterogeneity of the Plasmodium falciparum circumsporozoite protein: relevance for vaccine development , 1992, Infection and immunity.
[110] A. Holder,et al. A malaria merozoite surface protein (MSP1)-structure, processing and function. , 1992, Memorias do Instituto Oswaldo Cruz.
[111] A. Hughes,et al. Circumsporozoite protein genes of malaria parasites (Plasmodium spp.): evidence for positive selection on immunogenic regions. , 1991, Genetics.
[112] A. Holder,et al. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion- inhibiting antibodies , 1990, The Journal of experimental medicine.
[113] C. Newbold,et al. Wild isolates of Plasmodium falciparum show extensive polymorphism in T cell epitopes of the circumsporozoite protein. , 1989, Molecular and biochemical parasitology.
[114] R. Anders,et al. Integral membrane protein located in the apical complex of Plasmodium falciparum , 1989, Molecular and cellular biology.
[115] T. McCutchan,et al. Lack of cross-reactivity between variant T cell determinants from malaria circumsporozoite protein. , 1988, Journal of immunology.
[116] P. Caspers,et al. Human T cells recognize polymorphic and non‐polymorphic regions of the Plasmodium falciparum circumsporozoite protein. , 1988, The EMBO journal.
[117] J. Berzofsky,et al. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[118] T. McCutchan,et al. Sequence variation in putative functional domains of the circumsporozoite protein of Plasmodium falciparum. Implications for vaccine development. , 1987, The Journal of biological chemistry.
[119] K. Tanabe,et al. Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum. , 1987, Journal of molecular biology.
[120] R. Schwarz,et al. Strain variation in the circumsporozoite protein gene of Plasmodium falciparum. , 1987, Molecular and biochemical parasitology.
[121] J. Rothbard,et al. Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum. , 1985, Science.
[122] R. Carter,et al. Biosynthesis of the target antigens of antibodies blocking transmission of Plasmodium falciparum. , 1984, Molecular and biochemical parasitology.
[123] J. Weber,et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. , 1984, Science.
[124] G. Uilenberg,et al. Studies on Theileriidae (Sporozoa) in Tanzania. X. A large-scale field trial on immunization against cattle Theileriosis. , 1977, Tropenmedizin und Parasitologie.